Centient

Centient is a clinical-stage biotechnology company dedicated to developing non-opioid therapies for chronic pain management. Formerly known as Centrexion Therapeutics, the company focuses on novel mechanisms of action to provide potent and durable pain relief without the side effects or addiction risks associated with opioids. Its lead program, CNT-001, is a synthetic capsaicin injection in Phase 3 clinical trials for osteoarthritis of the knee. Centient's broader pipeline includes small molecule inhibitors and agonists targeting TRPV1, SSTR2, and Nav1.7 pathways to address various inflammatory and neuropathic pain conditions.